Find a Doctor Find a Doctor
Time to see a specialist? Time to see a specialist?
We found [COUNT] Specialists
who treat [INTEREST]
We found [COUNT] Specialists
who treat [INTEREST]
[TELEHEALTH] offer Telehealth options.
Treating Metastatic Breast Cancer

This content is created by Healthgrades and brought to you by an advertising sponsor. More

This content is created or selected by the Healthgrades editorial team and is funded by an advertising sponsor. The content is subject to the Healthgrades medical review process for accuracy, balance and objectivity. The content is not edited or otherwise influenced by the advertisers appearing on this page except with the possible suggestion of the broad topic area. For more information, read the Healthgrades advertising policy.

Metastatic Breast Cancer: 8 Things Doctors Want You to Know

Doctor William C Lloyd Healthgrades Medical Reviewer
Medically Reviewed By William C. Lloyd III, MD, FACS
Written By Lorna Collier on September 6, 2020
  • Woman having mammogram performed
    New treatments for stage 4 breast cancer are bringing new hope.
    Nearly 270,000 people in the United States—almost all women—are expected to be diagnosed with invasive breast cancer in 2018, and about 40,000 will die from it. Breast cancer is the second most common cause of cancer death in American women, and most of those cases are due to metastatic cancer that has spread beyond the breast to other areas of the body. Yet, new treatments over the past few years are making a big difference in transforming metastatic breast cancer into a chronic, manageable disease—and extending survival rates significantly. Two breast cancer oncologists who both treat and research this cancer explain more about these promising new treatments.
  • Nurse prepares syringe for an injection
    1. “In the last 3 to 5 years, there's been an explosion of new treatment options for metastatic breast cancer.”
    A variety of new drugs approved in recent years to treat metastatic breast cancer "really have been game-changers," says Cesar A. Santa-Maria, MD, a breast oncologist and researcher at the Sidney Kimmel Cancer Center at Johns Hopkins. These targeted therapies attack tumors based on their specific metabolic characteristics, preventing cancer cells from growing and spreading. As a result, many patients have experienced "good disease control in the metastatic setting for long periods of time," Dr. Santa-Maria says, with fewer side effects than with older medications and chemotherapy.
  • Worried woman with doctor
    2. “Your treatment depends on what subtype of breast cancer you have.”
    Breast cancer is "not one disease—it's a bunch of different diseases," says Kathy Miller, MD, oncologist, researcher and professor of oncology at Indiana University School of Medicine. Most breast cancers (about 70%) are sensitive to hormones, such as estrogen and progesterone. Some cancers (about 15% to 20%) may also contain an extra growth factor called HER2 (human epidermal growth factor), which Dr. Miller says is "like a gas pedal stuck in the 'on' position," causing tumors to grow very quickly. About 10% to 15% of breast cancers aren't sensitive to estrogen, progesterone or HER2, so they are called triple-negative. Your treatment will vary depending on your metastatic breast cancer's type.
  • Your Opinion Matters!
    In order to improve our content, we want to hear from you. Please take this short anonymous survey to let us know how we’re doing.
    Take the survey!
  • African American women at breast cancer awareness event
    3. “HER2-positive breast cancer is much more treatable today than it used to be.”
    Dr. Miller says before the advent of HER2-positive targeted therapy, she'd pray a patient's tumor would not turn out to be HER2-positive, because of the poor prognosis. "Now it's exactly the opposite," says Dr. Miller. "You find yourself praying, 'Please let it be HER2-positive, because I have so much more I can do for this woman.' It's really changed." Dr. Miller says newer targeted therapies have boosted average survival from 18 months to 5 years—with some women living many years longer. "It's really been phenomenal," she says.
  • Medicines in hand
    4. “Anti-hormone therapy is helping patients with hormone-positive metastatic disease live longer.”
    Patients with hormone receptor-positive breast cancer are typically given anti-hormone therapy to block hormonal effects, but over time, "The cancer will outsmart the drug and it will be able to grow despite treatment," says Dr. Santa-Maria. However, in the past few years, drugs have become available that help fight this hormone resistance, making the hormone therapy last longer. Drugs such as CDK4/6 inhibitors are given along with anti-hormone therapy and have "really changed the treatment landscape" for metastatic hormone-receptor positive breast cancer, he says. In some patients, these newer treatments have doubled the amount of time they can be on hormone therapy, from about a year on average to two years, with generally manageable side effects (such as low white blood cell counts and being tired).
  • Stem cell research for the treatment of cancer
    5. “Triple-negative breast cancer may soon be treated by immunotherapy.”
    Dr. Miller dislikes the term "triple-negative breast cancer," which patients may mistakenly think is "three times as bad" as other breast cancers, she says. However, because this subtype doesn't respond to the targeted therapies currently available, it is "historically the toughest breast cancer to treat," says Dr. Santa-Maria. Right now, the standard treatment is chemotherapy. One promising area of research, though, is immunotherapy for triple-negative breast cancer. Dr. Santa-Maria says some patients in clinical trials are responding very well to this treatment, which he hopes will be available "sooner rather than later."
  • Looking into microscope
    6. “There is a new treatment for metastatic breast cancer patients with BRCA mutations.”
    Some patients with breast cancer have genetic defects in the BRCA1 or BRCA2 genes. Researchers have found that patients with BRCA mutations who have metastatic breast cancer may benefit from treatment with PARP inhibitors, says Dr. Santa-Maria. Because of this new treatment, doctors may recommend some women with metastatic breast cancer undergo genetic testing to see if they have the BRCA mutation. "That's the only way to know if they might benefit from this group of targeted therapies," says Dr. Miller. Dr. Santa-Maria says several top universities have recently begun studying whether cancer caused by other mutations, not just BRCA, may also respond to PARP inhibitors.
  • senior woman looking at bone xray with doctor
    7. “Surgery is not typically done for metastatic tumors unless they are bothering you.”
    Metastatic breast cancer is a "systemic disease," says Dr. Santa-Maria. It uses your bloodstream and lymphatic system to travel around your body, and may cause tumors to grow in various organs. Doctors typically won't do surgery on these tumors or radiate them because, Dr. Santa-Maria says, "It's almost like whack-a-mole—as you get one lesion out, you'd likely have another lesion develop elsewhere." Instead, other treatments, such as chemotherapy and targeted therapy, or combinations of these drugs, are used to shrink and control the tumors. If, however, a tumor is painful or causing symptoms, doctors may remove it, he says.
  • Doctor and patient using digital tablet in clinic
    8. “Clinical trials are a way to get access to new drugs and treatments, while helping future patients.”
    Some patients think if they enroll in a clinical trial, they risk getting stuck in the control group and receiving just "a placebo or a sugar pill," says Dr. Miller. But clinical trial patients typically get either experimental treatment or the current standard of care for their cancer. It's also often the only way to access many of the new drugs being studied, such as immunotherapy for breast cancer, says Dr. Santa-Maria. Both he and Dr. Miller strongly encourage cancer patients to look into clinical trials (found via the American Cancer Society website Trusted Source American Cancer Society Highly respected international organization Go to source or by contacting your physician). Besides helping yourself, research also moves cancer treatment forward, points out Dr. Miller, enabling future patients with metastatic breast disease to find better, more long-lasting, and perhaps even curative treatments.
8 Things Metastatic Breast Cancer Doctors Want You to Know
  • Assistant professor of oncology at Johns Hopkins University, specializing in breast cancer; board-certified in internal medicine and oncology.

    View My Profile on Healthgrades
  • Ballve Lantero Professor of Oncology at the Indiana University School of Medicine; also associate director of clinical research at the Indiana University Simon Cancer Center, focusing on breast cancer treatment.

  1. Hormone therapy for breast cancer. American Cancer Society.
  2. Role of PARP Inhibitors in Triple-Negative Breast Cancer. OncoTherapy Network.
  3. CKD4/6 inhibitors for treatment of metastatic breast cancer. Susan G. Komen Breast Cancer Foundation.
  4. Triple-Negative Breast Cancer.
  5. Breast Cancer - Metastatic: Statistics. (American Society for Clinical Oncology).
  6. Breast Cancer - Metastatic: Introduction. (American Society for Clinical Oncology).
Was this helpful?
Last Review Date: 2020 Sep 6
THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment. Never ignore professional medical advice in seeking treatment because of something you have read on the site. If you think you may have a medical emergency, immediately call your doctor or dial 911.